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ABSTRACT DSM265 is a novel antimalarial drug in clinical development that acts as
a selective inhibitor of Plasmodium dihydroorotate dehydrogenase. In a previous
phase 1b study, a single 150-mg dose of DSM265 showed partial efficacy against ex-
perimentally induced blood-stage Plasmodium falciparum malaria (IBSM). Pharmaco-
kinetic/pharmacodynamic modeling predicted a human efficacious dose of 340 mg.
The primary objectives of the current study were to determine the safety and effi-
cacy of a single oral 400-mg dose of DSM265 against P. falciparum in the IBSM
model. Eight healthy participants were inoculated intravenously with 2,800 parasites
and treated with DSM265 7 days later. Unexpectedly, one participant did not de-
velop parasitemia during the study. All other participants developed parasitemia,
with the complete clearance of asexual parasites occurring following DSM265 treat-
ment. All seven subjects also became gametocytemic. The secondary objectives
were to investigate the gametocytocidal and transmission-blocking activity of a sec-
ond 400-mg dose of DSM265, which was administered 23 days after inoculation. Ga-
metocytes were not cleared by the second dose of DSM265, and transmission-
blocking activity could not be determined due to low gametocyte densities. Three
DSM265-related adverse events occurred, including a cutaneous rash in one subject
on the day of the second DSM265 dose. The results obtained in this study support
the prediction of the efficacious dose of DSM265 and provide further evidence that
DSM265 is generally safe and well tolerated. In addition, this study confirms preclini-
cal data indicating that DSM265 permits the development and maturation of game-
tocytes and does not clear mature circulating gametocytes. (This study has been
registered at ClinicalTrials.gov under identifier NCT02573857.)
KEYWORDS CHMI, DSM265, IBSM, antimalarial agents, blood stage, gametocytes,
malaria, transmission, volunteer infection study
Despite advances in malaria prevention and treatment, in the last 5 years globalprogress in malaria control has stalled (1). Malaria is still responsible for a large
burden of morbidity and mortality worldwide, with an estimated 216 million cases and
442,000 deaths occurring in 2016 (1). Achieving the long-term goal of malaria elimi-
nation is hampered by many factors, and of particular concern is the development and
spread of antimalarial drug resistance (2). The development of new antimalarial treat-
ments with novel mechanisms of action remains a high priority, with several candidates
currently under clinical development (reviewed in reference 3). The required properties
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of new antimalarial molecules have been defined by outlining a number of target
candidate profiles (TCPs) and their intended use in targeting different stages of the
malaria parasite life cycle (4). Although accepted as an ambitious goal, the ideal
antimalarial treatment would be delivered as a single dose, have activity against
multiple parasite life cycle stages, and prevent new infection. Ideally, at the time of
treating the asexual parasite infection, the drug used would also prevent the develop-
ment of the transmissible stage of the malaria parasite (gametocytogenesis), clear
mature gametocytes, or block transmission to mosquitoes by rendering the gameto-
cytes sterile. (4). As we move toward elimination, drugs with such activity are highly
desirable (5). However, at present, the only licensed antimalarial able to clear mature
gametocytes is primaquine (0.25 mg/kg of body weight) (6, 7).
DSM265 is a triazolopyrimidine inhibitor of the Plasmodium dihydroorotate dehy-
drogenase (DHODH). DHODH is an enzyme that is essential in Plasmodium species for
pyrimidine synthesis, as the pyrimidine salvage pathway is absent in these organisms
(8). Preclinical studies indicated that DSM265 is highly selective for Plasmodium DHODH
and has activity against both the blood and liver stages of Plasmodium falciparum (9,
10). In vitro studies also indicated that DSM265 lacks activity against early-stage or
mature infectious gametocytes but may inhibit oocyst development, thereby poten-
tially providing transmission-blocking activity (10). Four clinical trials investigating the
safety and efficacy of DSM265 in humans as either prophylaxis or blood-stage treat-
ment have been performed, but these did not specifically assess the effect of DSM265
on gametocytemia (11–13). In the first-in-human study in healthy participants, single
oral doses between 25 and 1,200 mg were safe and well tolerated and demonstrated
a long elimination half-life (t1/2) of approximately 5 days. Using the induced blood-
stage malaria (IBSM) model, a single 150-mg dose of DSM265 was effective in clearing
asexual P. falciparum parasites, with recrudescent infections developing in all partici-
pants and detection of gametocytes being reported after DSM265 treatment (11). In
that study, the MIC of DSM265 in blood was estimated to be 1.04 g/ml, resulting in a
predicted single efficacious dose of 340 mg. Two further phase 1b clinical trials dem-
onstrated good prophylactic activity of DSM265, with complete protection being
achieved when a single 400-mg dose was administered 1 day prior to sporozoite
challenge and partial protection being achieved when it was administered 3 or 7 days
prior to challenge (12, 13). In a phase 2a study where the efficacy of DSM265 against
acute uncomplicated P. falciparum infection was evaluated in Peru (14), a single dose
of DSM265 rapidly cleared most infections. All 11 patients who received a 400-mg dose
achieved a PCR-adjusted adequate clinical and parasitological response (ACPR) by day
14, and 8 of 10 patients receiving a 250-mg dose achieved an ACPR by day 14. Over an
observation period of 28 days, 1 of 11 patients in the 400-mg-dose cohort experienced
recrudescence and 3 of 10 patients in the 250-mg-dose cohort experienced recrudes-
cence. These studies all demonstrate the safety of DSM265 and support the evaluation
of the predicted efficacious dose of DSM265.
Therefore, the present study aimed to evaluate the safety, tolerability, pharmacoki-
netic (PK) profile, and efficacy of a single 400-mg dose of DSM265 in a volunteer
infection study where the P. falciparum parasites were intravenously inoculated. More-
over, we investigated the activity of DSM265 against gametocyte development and
maturation and also explored the ability of a second 400-mg dose of DSM265 to clear
gametocytemia and block transmission to Anopheles vector mosquitoes.
RESULTS
Study participants. This study was conducted from 11 November 2015 to 16
December 2015 in eight healthy malaria-naive adults. The majority of participants were
Caucasian (7 participants), 5 were male, and the mean age was 24.8 years (Table 1). All
eight participants were inoculated intravenously with 2,800 viable P. falciparum-
infected red blood cells on day 0. In five participants, blood-stage parasitemia was first
detected by 18S ribosomal DNA (rDNA) quantitative PCR (qPCR) on day 4 postinocu-
lation, with a further two participants becoming qPCR positive on day 5. One partici-
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pant did not develop detectable blood-stage parasitemia at any time during the study.
This participant retrospectively reported an undisclosed history of azithromycin usage
prior to inoculation. A retrospective assay for azithromycin from a plasma sample
collected on day 0 did not reveal measurable drug. In addition, the participant’s blood
was shown to support the growth of P. falciparum when used for in vitro parasite
culture, suggesting that this participant does not have red blood polymorphisms that
inhibit parasite growth. All eight participants were treated with an initial 400-mg dose
of DSM265 on day 7; the participant that did not develop parasitemia was dosed in
order to assess the safety and pharmacokinetics of DSM265. The seven participants who
developed blood-stage parasitemia received a second 400-mg dose of DSM265 on day
23 to investigate its activity against mature gametocytes. At the end of the study (day
28), all eight participants received systematic rescue treatment with artemether-
lumefantrine and primaquine.
Safety. Overall, the study showed that DSM265 was generally safe and well toler-
ated. No serious adverse events (SAEs) were reported. A total of 88 adverse events (AEs)
which were mostly mild in severity (87.5%) were reported (see Table S1 in the
supplemental material), and the majority were deemed related to malaria parasite
infection (77.3%). Eleven AEs were moderate in severity, while none were classified as
severe. There were no abnormal laboratory or electrocardiogram (ECG) findings that
were considered clinically significant. Two participants reported AEs considered to be
possibly related to DSM265 treatment. Mild abdominal tenderness was reported for
one participant on the day of initial dosing with DSM265; this lasted approximately 3
days, before resolving spontaneously without intervention. One other participant
developed a generalized rash and pruritus on the day of the second DSM265 dose,
approximately 3 h after dosing. This skin reaction was of moderate severity and
resolved after approximately 12 h with cetirizine and promethazine hydrochloride use.
The severity of the malaria symptoms and signs experienced by the participants
during the study was generally mild, as assessed by use of a clinical scoring tool. At the
time the first dose of DSM265 was administered, 4 of the 7 participants who were
parasitemic had no malaria symptoms or signs (clinical score, 0), while the remaining 3
participants each had a score of 3 (Table S2). The peak malaria clinical score recorded
during the study was 8; this was recorded for a single participant approximately 36 h
after administration of the first dose of DSM265.
Pharmacokinetic profile of DSM265. The plasma pharmacokinetic profile of DSM265
was characterized in all participants from the time of the initial dose of DSM265 until the
time of administration of the second dose (Fig. 1). The mean peak DSM265 plasma
concentration was 10 g/ml, which occurred at a median of 2 h postadministration. The
area under the concentration-time curve from 0 h extrapolated to infinity (AUC0–∞) was
estimated to be 1,808 g·h/ml, and the mean terminal half-life was estimated to be
140.3 h (Table 2).
TABLE 1 Participant characteristicsa
Characteristic Value
Mean (SD) age (years) 24.8 (4.0)
No. (%) of patients by sex
Male 5 (62.5)
Female 3 (37.5
No. (%) of patients by race
White 7 (87.5)
Asian 1 (12.5)
Mean (SD) BMI (kg/m2) 23.4 (2.0)
Mean (SD) ht (cm) 176.5 (14.7)
Mean (SD) wt (kg) 73.1 (11.5)
aData are for 8 participants. BMI, body mass index.
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Pharmacodynamic activity of DSM265. Among the seven participants who be-
came parasitemic, the geometric mean parasitemia upon initial dosing with 400 mg
DSM265 was 7,851 parasites/ml (95% confidence interval [CI], 2,245 to 27,462 parasites/
ml). A reduction in parasitemia was observed within 48 h of DSM265 administration,
with complete clearance occurring in all seven participants (Fig. 2). No recrudescent
asexual parasitemia developed in any participant. The absence of asexual para-
sitemia was confirmed by determining that SBP-1 mRNA transcripts—present only
in ring-stage parasites (15, 16)—were absent on day 20. The regression models of
the log-linear relationship of parasite decay for the 7 participants who became
parasitemic were significant (P 0.001), thereby permitting calculation of the
parasite reduction ratio (PRR). The overall cohort-specific ratio of the parasite
density at admission and the parasite density 48 h after antimalarial treatment
(log10 PRR48) was 2.78 (95% CI, 2.61 to 2.95), with a corresponding parasite
clearance half-life of 5.20 h (95% CI, 4.90 to 5.53 h).
Effect of DSM265 on gametocytes. Following the clearance of asexual parasitemia,
male and female gametocytes were detected in all seven participants, with low but
relatively stable gametocytemia beginning from approximately day 16 after inoculation
(9 days after initial DSM265 administration; Fig. 3A and B). The geometric mean level of
gametocytemia on day 20 was 105 gametocytes/ml (range, 15 to 937 gametocytes/ml).
Peak gametocytemia correlated with asexual parasitemia on the day of DSM265 dosing
(day 7), suggesting a relatively consistent gametocyte conversion rate among the
participants (Spearman’s r 0.964, P 0.003; Fig. 3C). Male gametocytes were present
at lower densities than female gametocytes (Fig. 3A and B). In samples where both male
and female gametocyte levels exceeded 100 gametocytes/ml, calculated gametocyte
sex ratios were heavily female biased, with a mean of 1 male to 16 female gametocytes
FIG 1 DSM265 plasma concentration-time profiles. Participants received a single dose of DSM265 at
400 mg on day 7. The lines indicate the DSM256 concentration in plasma over time for each participant
following DSM265 dosing (n 8).
TABLE 2 Noncompartmental pharmacokinetic analysis of DSM265 plasma concentration-
time profilesa
Parameter Value
Cmax (ng/ml) 9,986 (7,813–14,504)
tmax (h) 2 (1–24)
AUC0–∞ (ng·h/ml) 1,807,590 (1,598,235–2,049,829)
AUC0–last (ng·h/ml) 1,544,339 (1,354,506–1,854,997)
t1/2 (h) 140 (106–164)
aThe data represent the geometric mean (range) for all parameters except tmax, for which the data represent
the median (range). Participants (n 8) were treated with a single dose of DSM265 on day 7. The data
included in the PK analysis encompass time points from the day of treatment until the day of second dose
administration. Abbreviations: AUC0–last, the area under the concentration-time curve from 0 h up to the
last time point measure; AUC0–∞, area under the concentration-time curve from 0 h extrapolated to infinity;
t1/2, elimination half-life; Cmax, maximum plasma concentration; tmax, the time point when Cmax was
reached; t1/2, elimination half-life.
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(range, 1:8 to 1:63; Fig. 3D). Administration of a second 400-mg dose of DSM265 on day
23 (geometric mean, 80 gametocytes/ml; range, 12 to 915 gametocytes/ml) did not
result in a decrease in male or female gametocyte densities. All participants subse-
quently received systematic rescue treatment with artemether-lumefantrine and a
FIG 2 Time course of asexual parasitemia. Participants were inoculated with 2,800 viable parasites on
day 0, and a single 400-mg dose of DSM265 was administered on day 7 (indicated by the vertical dashed
line). Blood-stage parasitemia development and clearance were monitored by 18S rDNA qPCR. Thin lines
represent each of the 7 participants who developed parasitemia, and the bold line represents the
geometric mean.
FIG 3 Gametocytemia. (A, B) The gametocyte density was quantified using qRT-PCR assays specific for female gametocytes
(pfs25) (A) and male gametocytes (PfMGET) (B). The first vertical dashed line indicates the day of the second dose of 400 mg
DSM265 (day 23), and the second vertical dashed line indicates the end of study primaquine treatment (day 28). Thin lines
represent curves for the individual participants, and the bold line is the geometric mean. (C) Comparison of peak
gametocytemia (total number of gametocytes [gct] per milliliter measured by 18S rDNA qPCR) to asexual parasitemia at
the time of treatment (18S rDNA qPCR). (D) The proportion of male (blue bars) and female (red bars) gametocytes was
determined in the 12 samples where male and female gametocyte densities exceeded 100 gametocytes/ml. The samples
were from participants R102, R103, and R107 and were taken at multiple time points between day 16 and day 26.
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single 45-mg dose of primaquine on day 28, which resulted in clearance of the
gametocytes.
Transmission of parasites to Anopheles stephensi mosquitoes. To evaluate the
transmission-blocking activity of DSM265, mosquito feeding assays were performed
during the period of stable gametocytemia, before and after the second 400-mg dose
of the drug. Direct skin feeding assays (DFA) were performed on days 20 and 28, while
direct membrane feeding assays (DMFA) were performed on days 20, 23, and 28. The
mosquitoes fed well on the blood, with a median feeding rate of 100% for the DFA and
97.2% for the DMFA. Mosquito colony health was confirmed by demonstration of low
adult mosquito mortality at the time of midgut dissection (median mortality rate, 7.7%
for the DFA and 10.3% for the DMFA; Table S3). The rate of mosquito infection was
evaluated 7 to 10 days after the feeding assay by assessing the presence of midgut
oocysts using 18S rDNA qPCR. Oocysts were not detected in any mosquito midgut
either before or after DMS265 dosing. This is likely due to the gametocyte densities at
the time of feeding being below the level known to reliably result in transmission to
mosquitoes.
DISCUSSION
This study demonstrated that a single oral dose of 400 mg DSM265 is sufficient to
completely clear low-level P. falciparum parasitemia (1,230 to 61,357 parasites/ml on
the day of treatment) following experimentally induced blood-stage infection in
healthy malaria-naive participants. Pharmacodynamic analysis indicated that DSM265
administration resulted in a modest rate of parasite clearance, with an overall cohort-
specific log10 PRR48 of 2.78 and a corresponding parasite clearance half-life of 5.2 h. This
was faster than the clearance rate observed when 150 mg of DSM265 was administered
(log10 PRR48, 1.55; parasite clearance half-life, 9.4 h) and similar to the activity of other
long-acting drugs that have been tested in the IBSM model, such as mefloquine
(10 mg/kg; log10 PRR48, 2.34, parasite clearance half-life, 6.2 h) (11) and ferroquine
(800 mg; log10 PRR48, 2.21, parasite clearance half-life, 6.5 h) (17). Importantly, no
subjects developed recrudescent parasitemia following administration of a 400-mg
dose of DSM265 in this study, which supports the predicted efficacious dose calculation
from the preceding study (11). Furthermore, the parasite clearance rate observed in the
present IBSM study is similar to that observed when DSM265 at 400 mg was adminis-
tered to patients with P. falciparum infection in Peru (median log10 PRR48, 2.9; median
parasite clearance half-life, 5.0 h) (14), thereby providing further experimental valida-
tion of this system. The pharmacokinetic profile of DSM265 in the current study
corresponds closely to results obtained in the other published studies (11–14).
DSM265 was generally safe and well tolerated at the 400-mg dose level, with no
SAEs or severe AEs being reported and with only 3 AEs that were considered related to
DSM265 treatment (mild abdominal tenderness and moderate skin rash/pruritus) being
reported in 2 subjects. The onset of a rash that had some features consistent with a
drug reaction (due to the fact that it occurred soon after the second dose of DSM265)
raised the possibility of an IgE-mediated immunoallergic reaction. A follow-up com-
prehensive skin prick test study was performed in this particular subject to investigate
if this reaction was due to a hypersensitivity reaction to DSM265. The results of that
study will be reported separately. The overall favorable safety profile for DSM265
observed in this study agrees with the safety findings from the previous clinical studies
(11–13). In the first-in-human study, 55 participants were administered DSM265 at
doses ranging from 25 to 1,200 mg; 15 drug-related adverse events were reported, with
the most common being headache, while all other drug-related events were reported
only once (11). In the first chemoprophylaxis study, 11 participants were treated with
400 mg DSM265, and only 1 participant experienced an adverse event that was
considered related to DSM265 (moderate transient elevation in serum bilirubin) (13).
Eighteen participants received 400 mg DSM265 in the second chemoprophylaxis study;
nine AEs were considered possibly related to DSM265, and these were mild to mod-
erate headache or gastrointestinal events (12). There were no specific safety concerns
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reported in the recently completed phase 2a study, in which single doses of DSM265
at 250 to 800 mg were administered to 45 malaria patients in Peru (14). Together, the
safety results obtained from the clinical studies performed to date indicate that
DSM265 is generally safe and well tolerated when administered orally to human
participants.
After the clearance of asexual parasites, gametocytemia was observed in all partic-
ipants, suggesting that DSM265 at 400 mg does not inhibit gametocytogenesis. Male
gametocytes were detected at lower densities than female gametocytes, in accordance
with the female-biased sex ratios often seen during natural infections (18, 19). However,
the gametocyte sex ratios observed in this study (male/female 1:16) were more
female biased than those normally reported for natural infections (male/female 1:5)
and more female biased than those detected in a previous IBSM study using the same
P. falciparum 3D7 parasite line, where transmission to mosquitoes was also investigated
(male/female 1:4) (20). While it is possible that DSM265 treatment may have exerted
a differential effect on male and female gametocytes and that this may have contrib-
uted to the observed absence of transmission, but this study was not powered to
determine this effect. In order to evaluate the gametocytocidal activity of DSM265, an
additional 400-mg dose was administered to participants when they were gameto-
cytemic (day 23). In the 5 days following administration of the second dose, the
gametocyte numbers remained stable (10 to 1,000 female gametocytes/ml and 1 to 100
male gametocytes/ml), indicating that DSM265 does not clear mature gametocytes.
The lack of gametocyte clearance activity by DSM265 agrees with previous in vitro
studies which indicated that the drug had no activity against either early- or late-stage
gametocytes (10) and is consistent with the mechanism of action of DSM265 in
blocking pyrimidine nucleotide synthesis, which is downregulated in nonreplicating
gametocytes (21). Although gametocyte clearance was not observed, DMS265 at
400 mg (either the first or the second treatment) may have damaged or sterilized the
gametocytes, thereby inhibiting oocyst formation, as has been reported from in vitro
studies (10). However, in this trial, oocysts were not detected in mosquitoes fed either
before or after the second dose of DSM265, so it was therefore not possible to
determine the effect of DSM265 on transmission. The lack of transmission could also be
attributable to the relatively low level of gametocytemia observed in this study (day 20
geometric mean, 105 gametocytes/ml; range, 15 to 937 gametocytes/ml). This is
supported by our previous data, where transmission did not occur at gametocyte
densities below 850 gametocytes/ml (20), and by reports of the transmissibility of
natural infections (22–24). The low level of gametocytemia observed is also in agree-
ment with the previously reported relationship between the asexual parasite biomass
at the time of treatment and the resulting gametocytemia, with asexual parasitemia at
the time of schizontocidal drug treatment being required to exceed 50,000 para-
sites/ml to result in levels of gametocytemia amenable to onward transmission (3,000
gametocytes/ml) (20). Enrichment of gametocytes using either density gradient cen-
trifugation or magnetic activated cell sorting prior to performing mosquito feeding
assays (20) could help in evaluating transmission to mosquitoes in this model in the
future. These assays could enable evaluation of the sterilizing effect of a drug on
gametocytes even in the presence of low densities.
The observation that one subject who received the P. falciparum blood-stage
inoculum in this study did not develop parasitemia represents a highly unexpected
result. It is the first time that a participant has not developed blood-stage parasitemia
in this model, with 326 subjects having developed PCR patency after intravenous
inoculation with this isolate. With this one failure in 326 challenges, statistical analysis
indicates a 95% confidence that the true failure rate does not exceed 1.4%. Although
we have not been able to definitively determine the cause of this failure, the possibility
of the refractoriness of the participant’s erythrocytes has been excluded. While the
possibility of an error in preparation or administration of the inoculum cannot be
excluded, syringes for all participants in each cohort were prepared as a single batch,
and intravenous injection in this participant took place without mishap. Finally, despite
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the fact that the participant retrospectively reported an undisclosed history of azithro-
mycin usage prior to inoculation, this drug could not be detected in the plasma sample
collected on day 0. However, azithromycin is known to be highly cell associated, and
therefore, the possibility of drug-induced inhibition of parasite growth cannot be
excluded. Two previous reports also exist of failure to induce experimental malaria
parasite infection due to undisclosed suspected quinine consumption (25, 26).
The limitations of this study include the low number of subjects, the use of the P.
falciparum 3D7 laboratory parasite strain, and the low levels of gametocytemia. Addi-
tionally, in order to fully evaluate the transmission-blocking activity in this model, a
control group is required. In this control group, gametocytes should be present in
transmissible numbers in participants who either have not received drug treatment or
have received a drug, such as piperaquine, that permits viable gametocyte develop-
ment and subsequent transmission. Drug activity could then be interpreted in the
context of expected transmission levels. Without this group, it is not possible to
definitively determine the reasons for low or no transmission.
In conclusion, this study aimed to investigate the safety and efficacy of the new
antimalarial drug DSM265 when administered as a single oral dose of 400 mg to
healthy malaria-naive participants experimentally infected with blood-stage P. falcipa-
rum and also evaluate its transmission-blocking activity. A 400-mg dose was shown to
be safe and well tolerated and to completely clear asexual parasitemia in all participants
without any recrudescence. DSM265 did not prevent the maturation of gametocytes,
nor did it clear mature circulating gametocytes. If further studies confirm that DSM265
lacks transmission-blocking activity, it will be important to combine this drug with
another agent that both prevents gametocytogenesis and kills mature gametocytes.
The main objective of new drug development is to provide new drugs to treat
patients in the event that the current artemisinin-based combination therapies (ACTs)
are no longer effective. It is important to note that although extensive Kelch mutations
are seen in Southeast Asia, the failure to respond clinically to ACT treatment is largely
linked to the failure of the partner drugs: amodiaquine, mefloquine, and piperaquine.
Both artemether-lumefantrine and pyronaridine-artesunate appear to maintain activity.
A second goal, in addition to providing new options to fight resistance, is to simplify
therapy, and a single-encounter therapy would clearly have significant advantages in
terms of directly observed therapy. It is important to underline that a molecule such as
DSM265 is capable of achieving a single-dose cure at a high dose, but this does not
preclude the possibility of its use in combination therapy over multiple days at lower
doses.
MATERIALS AND METHODS
Study design and participants. This was a phase 1b, open-label, IBSM clinical trial conducted at
Q-Pharm Pty. Ltd. (Brisbane, Australia) between October 2015 and June 2016 aiming to investigate the
antimalarial activity of DSM265 against P. falciparum. The second part investigated the antimalarial
activity of another investigational drug, OZ439, against P. vivax. The results of the second part will be
reported in a separate publication.
Healthy men and women (of nonchildbearing potential) aged 18 to 55 years were eligible for
inclusion in the study. Individuals were excluded if they had visited an area where malaria is endemic for
a period of longer than 2 weeks in the past 12 months or had received systemic therapy with a drug with
potential antimalarial activity in the past 6 weeks. Full inclusion and exclusion criteria for this study are
included in the supplemental material. All participants gave written informed consent before being
included in the study. This study was approved by the QIMR Berghofer Medical Research Institute Human
Research Ethics Committee and was registered at ClinicalTrials.gov (trial identifier NCT02573857).
Procedures. A cohort of 8 participants was inoculated on day 0 with P. falciparum-infected human
erythrocytes (approximately 2,800 viable parasites) as previously described (11). Parasite growth was
monitored by collecting blood samples and performing quantitative PCR (qPCR) targeting the gene
encoding P. falciparum 18S rRNA (18S rDNA qPCR) from day 4 after inoculation (27). Blood samples for
parasite quantification were collected before inoculation, on day 4, twice daily on days 5 and 6,
pretreatment on day 7 and 4, 8, 12, 16, 24, 30, and 36 h posttreatment, twice daily from day 9 to day 11,
and every 1 to 3 days until day 35.
Participants received a single oral 400-mg dose of DSM265 after an overnight fast when the
protocol-specified threshold for commencement of treatment was reached (parasitemia, 5,000 para-
sites/ml). The threshold was reached on day 7 in this study. DSM265 was supplied as 400 mg powder in
a bottle (Bend Research Inc., Bend, OR, USA). The powder was suspended in vehicle (0.1% methylcellulose
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[Methocel A4M], 0.1% polysorbate 80, 0.005% simethicone, 0.05% ethyl vanillin, 0.5% sucralose) to form
a 100-ml suspension for oral administration.
The clearance of parasitemia was measured by qPCR, and gametocytemia was monitored using
quantitative reverse transcriptase PCR (qRT-PCR) targeting Pfs25 mRNA, a transcript preferentially ex-
pressed in mature female gametocytes, and PfMGET mRNA, a transcript preferentially expressed in
mature male gametocytes (28). Interpolation of the transcript number to the gametocyte count was
undertaken as previously described (20). To distinguish recrudescent asexual parasitemia from gameto-
cytemia, qRT-PCR was performed to measure P. falciparum SBP-1 mRNA (15, 16, 20).
The gametocytocidal and transmission-blocking properties of DSM265 were assessed by adminis-
tering a second single oral dose of 400 mg DSM265 on day 23. The timing of this second dose was based
on the appearance of gametocytemia observed during the study. All participants received compulsory
rescue treatment with a 3-day course of artemether-lumefantrine (Riamet; Novartis Pharmaceuticals Pty.
Ltd., Macquarie Park, Australia) and a single 45-mg dose of primaquine (Primacin; BNM Group, Sydney,
Australia) at the end of the study on day 28.
Safety assessments were done at screening and at protocol-specified times. Safety parameters
included adverse events reporting, physical examination, vital signs, clinical laboratory evaluation,
electrocardiograms (ECGs), and malaria clinical score recording. The malaria clinical score served as a
clinical indication of the severity of the induced malaria parasite infection; 14 signs and symptoms
commonly associated with malaria were graded using a 3-point scale (0 absent, 1mild, 2mod-
erate, 3 severe), and the values were summed in order to generate an overall score (the maximum
possible score is 42).
Blood samples to determine the concentrations of DSM265 were taken before initial DSM265 dosing
and at the following time points postdosing: 1, 2, 4, 12, 24, 48, 96, 120, 168, and 384 h (before the second
dose). Plasma samples were analyzed by high-performance liquid chromatography-tandem mass spec-
trometry (HPLC-MS/MS) as previously described (11).
The transmission of parasites from participants to 3- to 7-day-old female Anopheles stephensi
mosquitoes was measured using both a direct feeding assay (DFA) and a direct membrane feeding assay
(DMFA) on day 20, day 23 (DMFA only), and day 28, as previously described (20). For DFAs, 35
mosquitoes were allowed to feed on the participant’s forearm for approximately 15 min. For the DMFA,
50 mosquitoes were allowed to feed on a water-jacketed membrane feeder filled with venous blood
collected into lithium heparin anticoagulant tubes. At 7 to 9 days after blood feeding, the mosquitoes
were dissected to quantify the oocysts in midgut preparations using 18S rDNA qPCR.
In vitro parasite culture. A venous blood sample was collected in lithium heparin from participant
R104 at the end of the study for use in an in vitro P. falciparum NF54 parasite culture, and parasite growth
in the participants’ blood was compared to parasite growth under normal culture conditions. Participant
blood or normal culture blood (Australian Red Cross) was washed and added to different culture flasks
at 5% hematocrit and 1% parasitemia in duplicate. Two days later, parasitemia was determined and all
flasks were subcultured. Two days later, parasite growth was compared between conditions.
Azithromycin quantitation in plasma sample. The concentration of azithromycin was determined
by hydrophilic interaction ultraperformance liquid chromatography (HILIC-UPLC) coupled with mass
spectrometry (Waters Corporation, Milford, MA, USA). Azithromycin was extracted from serum samples
using a methanol-containing labeled internal standard in a 96-well plate. A 1-l aliquot of the super-
natant was injected into the HILIC-UPLC system. Azithromycin was measured against a 7-point calibration
curve. The interrun imprecision (percent coefficient of variation) across 3 levels of quality control was
8%.
Outcomes. The primary endpoints were the safety, pharmacokinetics, and pharmacodynamics (PD)
associated with a single dose of 400 mg DSM265. The PK parameters determined using noncompart-
mental analysis were the maximum plasma concentration (Cmax), the time point when Cmax was reached
(tmax), the area under the concentration-time curve from 0 h up to the last time point measure (AUC0–last),
the area under the concentration-time curve from 0 h extrapolated to infinity (AUC0–∞), and the
elimination half-life (t1/2). The PD variables of interest in this study were the parasite reduction ratio (PRR)
and the parasite clearance half-life. PRR provides an estimate of the efficacy of an antimalarial treatment
and is the ratio of the parasite density between that at admission and that 48 h after antimalarial
treatment (expressed as the overall cohort-specific log10 PRR48). Secondary endpoints were the incidence
of transmission of gametocytes to Anopheles mosquitoes and the effect of a second dose of 400 mg
DSM265 on gametocytemia.
A further objective of this study was to define the PK/PD relationship of DSM265 in P. falciparum
parasite clearance. PK/PD modeling was performed using data from the current study in conjunction with
data from a previous IBSM study in which subjects were administered 150 mg DSM265 (11). The results
of this analysis are the focus of a separate report, which is in preparation.
Statistical analysis. The sample size of the current study (n 8) was comparable to that of previous
P. falciparum IBSM challenge studies and, based on previously published experience, was considered
sufficient for obtaining statistically meaningful data on the effects of DSM265 on malaria parasite kinetics.
Noncompartmental PK analysis was performed using R (version 3.3.1) and RStudio (version 0.99.903)
software. The area under the curve was determined using a trapezoidal method up to the last time point
measure (AUC0-last) and extrapolated to infinity (AUC0–∞). The gradient of the elimination phase was
determined by log-linear regression, leading to calculation of the elimination half-life (t1/2). The maximal
concentration following DSM265 administration (Cmax) and the time that it was reached (tmax) were
reported. All parameters were summarized using the geometric mean or median and range.
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The PRR and parasite clearance half-life were estimated using the slope of the optimal fit for the
log-linear relationship of the parasitemia decay (29). Individual PRR and the corresponding 95% CI were
calculated using the slope and corresponding standard error (SE) of the optimal regression model. The
cohort PRR and parasite clearance half-life were derived using the weighted mean of the optimal slope
for participants with an adequate model fit (P 0.001).
Two post hoc analyses were performed. To determine if the level of gametocytemia correlated with
the asexual parasitemia on the day of DSM265 dosing, Spearman’s rank correlation coefficient was
calculated. Furthermore, in samples where both male and female gametocytes exceeded 100 gameto-
cytes/ml, an estimation of the gametocyte sex ratios was performed.
SUPPLEMENTAL MATERIAL
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